Osher Van de Voorde Investment Management Acquires 598 Shares of Johnson & Johnson (NYSE:JNJ)

Osher Van de Voorde Investment Management lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 65,470 shares of the company’s stock after purchasing an additional 598 shares during the period. Johnson & Johnson accounts for about 3.5% of Osher Van de Voorde Investment Management’s portfolio, making the stock its 23rd largest position. Osher Van de Voorde Investment Management’s holdings in Johnson & Johnson were worth $8,471,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Phocas Financial Corp. boosted its holdings in Johnson & Johnson by 999,928.6% in the second quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock valued at $1,743,000 after acquiring an additional 125,161,066 shares during the last quarter. Nuveen Asset Management LLC boosted its holdings in Johnson & Johnson by 5,447.1% in the second quarter. Nuveen Asset Management LLC now owns 16,924,656 shares of the company’s stock valued at $2,357,266,000 after acquiring an additional 16,619,550 shares during the last quarter. Thoroughbred Financial Services LLC boosted its holdings in Johnson & Johnson by 14,147.0% in the second quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock valued at $401,425,000 after acquiring an additional 3,986,071 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Johnson & Johnson by 145.5% in the second quarter. Renaissance Technologies LLC now owns 4,341,162 shares of the company’s stock valued at $604,637,000 after acquiring an additional 2,572,695 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Johnson & Johnson by 11.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock valued at $2,895,870,000 after acquiring an additional 2,204,757 shares during the last quarter. Institutional investors own 72.05% of the company’s stock.

Shares of JNJ opened at $135.17 on Thursday. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99. The stock has a market cap of $344.99 billion, a P/E ratio of 16.52, a price-to-earnings-growth ratio of 2.21 and a beta of 0.69. The stock’s 50-day moving average price is $130.30 and its two-hundred day moving average price is $134.83.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The firm had revenue of $20.73 billion for the quarter, compared to analysts’ expectations of $20.14 billion. During the same quarter last year, the business earned $2.05 earnings per share. The company’s revenue was up 1.9% compared to the same quarter last year. As a group, equities analysts forecast that Johnson & Johnson will post 8.6 EPS for the current year.

JNJ has been the topic of several recent research reports. Morgan Stanley reiterated an “equal weight” rating and issued a $145.00 price target on shares of Johnson & Johnson in a report on Tuesday, August 27th. Atlantic Securities upgraded Johnson & Johnson from an “underweight” rating to a “neutral” rating in a report on Wednesday. Raymond James decreased their price target on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a report on Monday. Wells Fargo & Co decreased their price target on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Barclays initiated coverage on Johnson & Johnson in a report on Friday, June 21st. They issued a “hold” rating and a $140.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $150.91.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What does a dividend yield signify to investors?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.